Sutro Biopharma Files 2024 10-K, Details Key Partnerships
Ticker: STRO · Form: 10-K · Filed: Mar 13, 2025 · CIK: 1382101
| Field | Detail |
|---|---|
| Company | Sutro Biopharma, Inc. (STRO) |
| Form Type | 10-K |
| Filed Date | Mar 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, biotech, partnerships, financials
Related Tickers: VXY, MRK, ASTLF
TL;DR
Sutro Bio (STRO) filed its 2024 10-K. Looks like they're still working with Merck, Astellas, and Vaxcyte. Financials are in there.
AI Summary
Sutro Biopharma, Inc. filed its 2024 10-K on March 13, 2025, reporting on its fiscal year ending December 31, 2024. The company, focused on biological products, detailed its business operations and financial standing. Key relationships and agreements mentioned include those with Vaxcyte Inc., Merck KGaA, and Astellas. The filing also references equity securities and debt instruments.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of Sutro Biopharma's financial health, strategic partnerships, and operational performance for the fiscal year 2024.
Risk Assessment
Risk Level: medium — Biopharmaceutical companies often face inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2024-12-31 — Fiscal Year End (The period covered by the 10-K filing.)
- 2025-03-13 — Filing Date (The date Sutro Biopharma submitted its 10-K to the SEC.)
Key Players & Entities
- SUTRO BIOPHARMA, INC. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 20250313 (date) — Filing date
- Vaxcyte Inc. (company) — Mentioned in relation to common stock and agreements
- Merck KGaA (company) — Mentioned in relation to collaboration and license agreements
- Astellas (company) — Mentioned in relation to license and collaboration agreement financing component
FAQ
What were the key financial highlights for Sutro Biopharma in the fiscal year ending December 31, 2024?
The provided text does not contain specific financial figures for the fiscal year ending December 31, 2024, but indicates the filing covers this period and mentions various financial instruments and agreements.
What is the nature of Sutro Biopharma's relationship with Vaxcyte Inc. as detailed in the filing?
The filing mentions Vaxcyte Inc. in the context of common stock and equity securities for the period of January 1, 2024, to December 31, 2024.
What types of agreements does Sutro Biopharma have with Merck KGaA?
Sutro Biopharma has collaboration and license agreements, as well as supply agreements with Merck KGaA, Darmstadt, Germany, for the period of January 1, 2022, to December 31, 2022.
How is the Astellas license and collaboration agreement impacting Sutro Biopharma's financials?
The filing references a 'Financing Component On Unearned Revenue' related to the Astellas License and Collaboration Agreement for the period of January 1, 2023, to December 31, 2023.
What is Sutro Biopharma's primary business sector?
Sutro Biopharma, Inc. operates in the Biological Products (No Diagnostic Substances) sector, with SIC code 2836.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 13, 2025 regarding SUTRO BIOPHARMA, INC. (STRO).